Merck and Moderna release promising data on cancer vaccine trial

NPR | By Yuki Noguchi

Published October 23, 2026 at 6:56 PM EDT

A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system to go after cancer cells.

Yuki Noguchi

Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C.

See stories by Yuki Noguchi

WRVO runs on listener support.

WRVO is now well into its second year without federal funding. Through it all, our mission has stayed the same: serving central and upstate New York with trusted journalism, vital local coverage, and the diverse programming that informs and connects our communities. Listeners like you are what keep journalists on the ground, asking the hard questions that matter to our region.

Stand with public media and make your gift today. You'll be supporting more than yourself. You'll be supporting everyone who depends on WRVO as a trusted resource and civic cornerstone in central and upstate New York.

Support WRVO now